In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...
Read MoreIn a nutshell This study examined outcomes of nilotinib (Tasigna) as a second-line therapy over 2 years in patients with chronic myeloid leukemia (CML). The results of this observational study add valuable information to the body of evidence on the effectiveness of nilotinib after imatinib in patients with chronic-phase CML. Some background...
Read More
It has taken decades of work for researchers to find ways to activate the immune system to treat cancer (what we now call immuno-oncology or I-O). Much of that work has been poorly funded. Largely, it has been the result of researchers getting experience in other disciplines (like infectious disease) and then transferring that expertise to oncology...
Read More
Video information: While some chronic lymphocytic leukemia (CLL) patients are asymptomatic, the disease can cause a wide range of symptoms—and indicate disease progression. Dr. Stephen Spurgeon, from the OHSU Knight Cancer Institute, describes common CLL symptoms and their implications. Transcript Please remember the opinions expressed on...
Read More
Video information: Precision medicine allows for treatment plans to line up with a specific genetic profile. Find out from Dr. Michael Keating what is used to target CLL patients with a 17p deletion and when treatment should generally start. Dr. Keating also shares other genetic mutations to be aware of, and which tests are used to locate...
Read More
Video information: Every patient’s CLL is different, so how do doctors tell which CLL treatment is best? Dr. Kathryn Kolibaba, with Compass Oncology, and Dr. Stephen Spurgeon, from OHSU Knight Cancer Institute, discuss modern tests used to distinguish subtypes of CLL and find a therapy to match. The experts also share their thoughts on the...
Read More
Video Information: What is going on in the body of a person with chronic lymphocytic leukemia (CLL)? Increase your understanding of the condition as CLL experts Dr. Michael Keating and Dr. Kathryn Kolibaba break down the basics of the disease. Transcript: Andrew Schorr: So the idea is we have targeted therapy, and you knock back the cancer....
Read More
Video information: What are monoclonal antibodies targeting in the fight against CLL? Join us to hear from experts, Dr. Stephen Spurgeon and Dr. Jeff Sharman, as they dissect the scientific terminology that describes the monoclonal antibody family and their intended targets in the body. Transcript: Andrew Schorr: We have all these other drugs...
Read More
Video information: Inhibitors and targeted therapies have changed the landscape of CLL treatment, so what can patients expect from modern medicine? Dr. Jeff Sharman, from the US Oncology Network, joins our panel to explain the difference in design between newer therapies and chemotherapy. He also shares what newer medicines, like ibrutinib...
Read More
In a nutshell This is a European Society for Medical Oncology (ESMO) review of the treatment guidelines for elderly patients with malignant lymphoma. Some background The treatment for elderly patients (aged 70 or older) must be carefully adjusted to reduce side effects while still being effective. Many elderly patients may not be able to...
Read More
In a nutshell This study aimed to investigate the combination of blinatumomab (Blincyto) and a tyrosine kinase inhibitor in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia. This study concluded that this combination was safe and effective for this group of patients. Some background Philadelphia...
Read More
In a nutshell This study analyzed the results of 37 studies comparing myeloablative therapy and reduced intensity conditioning (RIC) before stem cell transplantation in patients with chronic lymphocytic leukemia (CLL). This study concluded that RIC was associated with lower mortality and better survival compared to myeloablative therapy. Some...
Read More
